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and Joanne F Aitken1,2,3Abstract
Background: The ability of medical practitioners to communicate risk estimates effectively to patients diagnosed
with melanoma relies on accurate information about prognostic factors and their impact on survival. This study
reports the development of one of the few melanoma prognostic models, called the Melanoma Severity Index
(MSI), based on population-based cancer registry data.
Methods: Data from the Queensland Cancer Registry for people (20–89 years) diagnosed with a single invasive
melanoma between 1995 and 2008 (n = 28,654; 1,700 melanoma deaths). Additional clinical information about
metastasis, ulceration and positive lymph nodes was manually extracted from pathology forms. Flexible parametric
survival models were combined with multivariable fractional polynomial for selecting variables and transformations
of continuous variables. Multiple imputation was used for missing covariate values.
Results: The MSI contained the variables thickness (transformed, explained 40.6% of variation in survival), body site
(additional 1.9% in variation), metastasis (1.8%), positive nodes (0.7%), ulceration (1.3%), age (1.1%). Royston and
Sauerbrei’s D statistic (measure of discrimination) was 1.50 (95% CI = 1.44, 1.56) and the corresponding RD2
(measure of explained variation) was 0.47 (0.45, 0.49), demonstrating strong explanatory performance. The Harrell-C
statistic was 0.88 (0.88, 0.89). Lacking an external validation dataset, we applied internal-external cross validation to
demonstrate the consistency of the prognostic information across geographically-defined subsets of the cohort.
Conclusions: The MSI provides good ability to predict survival for melanoma patients. Beyond the immediate clinical
use, the MSI may have important public health and research applications for evaluations of public health interventions
aimed at reducing deaths from melanoma.
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The incidence of cutaneous melanoma in Australia is
the highest in the world due to the combination of high
ultraviolet radiation, outdoor lifestyle and predomin-
ately Caucasian population [1]. As most melanomas in
Australia are diagnosed when thin, [2,3] overall survival
from melanoma is high. Internationally, overall five-year
survival estimates in Western countries exceed 85% [3-6],
although they are lower in Eastern Europe [7]. However* Correspondence: peterbaade@cancerqld.org.au
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unless otherwise stated.there remains an important subset of melanomas that
are diagnosed at an advanced stage, many with clinic-
ally apparent metastatic spread, for which the prognosis
is poor [3,8,9].
Prognostic models are used to assist clinicians with
their assessment of a patient’s future outcome and so en-
hance their informed decision making process with the
patient [10]. Most prognostic models for melanoma are
derived from selected clinical cohorts composed of pa-
tients referred to tertiary hospitals or specialist cancer
centres [11,12] and/or focussed on specific subgroups of
melanomas such as localised [13] or nodular melanoma
[14]. A similar limitation in regards to specific cohorts
of melanoma patients holds for population-based studies
of survival outcomes [2,15,16].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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model for deaths from melanoma among all patients di-
agnosed with a single invasive cutaneous melanoma in
Queensland, Australia, using data from a population-
based cancer registry, and discuss the potential applica-
tion in clinical practice and research.
Methods
Ethics approval to conduct this study was obtained
from the University of Queensland Behavioural & Social
Sciences Ethical Review Committee. Since these data
are not publically available, approval to access the required
data was obtained from the Queensland Department of
Health.
Data were obtained from the Queensland Cancer
Registry (QCR) for all patients in Queensland with a his-
tologically confirmed diagnosis of invasive melanoma
(C44, M872-879) for the period 1995 to 2008. Notifica-
tion of all cancers, apart from squamous and basal cell
cancer, is required by law. Melanomas diagnosed on the
basis of metastasis only were excluded. Variables ex-
tracted for each patient were sex, age at diagnosis, date
of diagnosis, anatomic sub-site of the melanoma, tumour
thickness, (Clarks) level of invasion and tumour morph-
ology. Information on ulceration, presence and extent of
metastasis at diagnosis and the number of positive
lymph nodes (local, regional or distal)at diagnosis was
extracted from pathology forms held by the Registry.
Due to the difficulty of attributing death to a specific
melanoma, we excluded all patients who were known
to have had more than one histologically confirmed
diagnosis of invasive melanoma since the establish-
ment of the QCR in 1982. As with a previous report
[2] only patients aged 15–89 years at diagnosis were
initially considered as there is evidence that melan-
oma survival outcomes are different for younger age
groups [17] and death certificates are less precise for
older patients [18].
The QCR database was matched against the Queensland
Register of Births, Deaths and Marriages and the National
Death Index to identify deaths in Queensland and inter-
state respectively up to 31st December 2010. Cause of
death was coded using all available information from death
certificates, autopsy reports and pathology reports.
Melanoma-specific survival was estimated from the
mortality of people diagnosed with melanoma between
1995 and 2008 (inclusive), with follow-up for all cases
to December 31, 2010. Patients who died before 31st
December 2010 from conditions other than melanoma
were censored at date of death. Those who were not re-
corded as dying by 31st December 2010 were censored
at this date.
Median follow-up time was calculated using the re-
verse Kaplan-Meier method [19]. All data analyses wereperformed using Stata/SE version 12.1 for Windows
(StataCorp, TX, USA). The Royston-Parmar models were
fitted using the stpm2 package [20,21].
Multiple imputation by chained equations
Due to missing values in the included variables (Table 1),
a complete case analysis would have excluded at least
30% of the initial cohort, potentially introducing a bias if
the excluded cases were a non-random sample.
We used multiple imputation [22] methods to deal
with the missing data, using the mi impute chained and
mi estimate commands for chained equations and subse-
quent regression model estimation. In the imputation
modelling we included the Kaplan-Meier estimate of the
survival curve, vital status, and the interaction between
the survival and vital status. All variables included in the
prognostic model were also included in the series of
chained imputation equations. We used n = 30 imputa-
tions based on the percentage of incomplete cases [23].
Predictive mean matching was used for the imputation
of thickness, logit models for lymph nodes (none vs one
or more) and ulceration (yes, no), and multinomial logit
models for Clark’s level and subsite.
Derivation of the survival model
Kaplan-Meier survival estimates, stratified by each of the
covariates, were calculated to describe the melanoma co-
hort. We then developed a multivariable survival model
to generate the prognostic index. Multivariable survival
analyses are generally carried out using Cox regression.
However several authors have highlighted the limitations
of this method for prognostic models, [21,24] particu-
larly relating to the appropriate modelling of the baseline
hazards function.
A parametric alternative to the Cox model, known as
a flexible parametric survival model, is fitted on the log
cumulative hazard scale [20,21]. These Royston-Parmar
(RP) models use natural cubic splines to estimate the
baseline cumulative hazard function. The selection of
scales and number of degrees of freedom for the baseline
spline function was made based on the Bayes informa-
tion criterion (BIC) statistic. For our data, the probit
scale with 3 degrees of freedom provided the best fit.
These 3 degrees of freedom equate to 2 interior knots
along with the 2 boundary knots.
We then ran a multivariable fractional polynomial
(MFP) procedure designed for multiple imputed data to
help guide the backwards selection of covariates, and
identify appropriate transformation(s), to retain in the
fully adjusted survival model [25,26]. To improve the fit,
we incorporated an additional smooth rank transform-
ation [27] which accommodates sigmoid dose–response
relationships. Visual inspection of the smoothed martin-
gale residuals for the regression models was also used to
Table 1 Cause-specific survival: invasive Melanoma in Queensland (1995–2008, follow-up to 2010)
Total 1 year survival 5 year survival 10 year survival
Total 28,654 (100%) 99.1 95.0 92.6
Gender
Male 16,269 (57%) 98.9 93.8 90.8
Female 12,385 (43%) 99.4 96.5 94.8
Age group (years)a
20-39 4,958 (17%) 99.8 97.4 96.1
40-59 10,814 (38%) 99.5 96.5 94.4
60-69 5,405 (19%) 99.1 94.6 91.7
70-79 5,006 (17%) 98.7 92.0 87.9
80-89 2,471 (9%) 97.5 88.6 85.2
Thicknessa
<=0.50 mm 12,641 (44%) 100 99.6 99.0
0.51-1.00 8,107 (28%) 99.9 97.9 96.2
1.01-1.50 2,487 (9%) 99.2 93.1 88.3
1.51-2.00 1,386 (5%) 98.8 87.9 80.3
2.01-4.00 2,234 (8%) 97.3 79.6 70.8
4.01+ 1,170 (4%) 92.9 67.8 61.4
Unknownb 629 (2%) 91.5 82.6 78.6
Body site
Scalp 565 (2%) 96.2 78.8 69.3
Face/Lip/Eyelid 2,221 (8%) 99.0 94.5 90.4
Ear/Neck 1,741 (6%) 98.9 93.4 90.6
Chest/Axilla 1,435 (5%) 99.2 96.0 94.0
Abdomen + Hip 791 (3%) 98.7 93.7 90.7
Back/Buttocks 8,046 (28%) 99.5 95.2 92.8
Upper arm/Forearm/Hand/Finger/sb.hand 3,644 (13%) 99.5 96.6 95.4
Foot/sb. foot/heel/toec 384 (1%) 97.4 87.7 79.6
Thigh/leg/ankle 5,961 (21%) 99.5 96.5 94.7
Shoulder 2,452 (9%) 99.5 96.0 93.7
Unknownb 1,414 (5%) 96.4 92.0 90.2
Morphology
Superficial spreading melanoma 16,229 (57%) 99.7 97.3 95.7
Nodular melanoma 2,415 (8%) 96.2 79.0 73.1
Malignant melanoma in junctional naevus 654 (2%) 99.7 98.0 97.1
Lentigo Maligna melanoma 1,688 (6%) 99.8 97.4 95.6
Acral lentiginous melanoma 144 (<1%) 97.9 85.5 80.2
Other specified melanoma 1,015 (4%) 97.5 87.6 79.8
Malignant melanoma NOS 6,509 (23%) 98.9 95.2 92.7
Ulceration
No ulceration 17,110 (60%) 99.7 97.3 95.5
Known ulceration 2,627 (9%) 95.4 77.0 70.7
No mention on pathologyb 8,917 (31%) 99.1 95.5 93.1
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Table 1 Cause-specific survival: invasive Melanoma in Queensland (1995–2008, follow-up to 2010) (Continued)
Clarks level
Into papillary dermis 15,488 (54%) 99.9 99.4 98.5
Filling papillary dermis 6,164 (22%) 99.6 95.3 92.7
Into reticular dermis 5,584 (19%) 98.0 86.6 80.3
Into subcutaneous fat 715 (3%) 93.4 70.0 60.7
Unknownb 703 (2%) 92.4 80.9 73.9
Positive nodes
None 28,421 (99%) 99.3 95.4 93.0
At least one 229 (<1%) 75.2 43.6 37.5
Metastasis
No 28,506 (99%) 99.3 95.3 92.9
Yes 148 (<1%) 68.7 39.4 27.6
Note: aModeled as a continuous variable in the prognostic model.
bActual values for missing data were estimated in the modeling process using multiple chained imputation.
csb = subungal; NOS = Not otherwise specified.
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tions of continuous covariates.
Finally, we used a forward selection process to investi-
gate whether the regression coefficients for any variables
depended on follow-up time using the approach de-
scribed by Royston & Parmar [20,21] with one degree of
freedom for the time dependent covariate effects. This
approach modifies the spline function of time used to
model the baseline distribution function and is imple-
mented using the stpm2t command in Stata. Covariates
without time dependence were included in the model in
standard fashion.
Discrimination
The discrimination of a prognostic model reflects its
ability to distinguish between patient outcomes, and is
closely related to the idea of the proportion of variance
that the model explains. We calculated Royston and
Sauerbrei’s D statistic [28] as a measure of discrimin-
ation, and R2D as a measure of explained variation on the
natural scale of the model [28]. We also calculated the
Harrel’s C discrimination index, which is a scored on a
scale of 0 to 1. This can be taken to mean that if two
cases are drawn at random, the c statistic is the prob-
ability that the person who survives the longest had the
highest predicted survival. Values near 0.5 suggest the
prognostic score is equivalent to a coin toss in determin-
ing which patient will live longer, while values near 0 or
1 indicate perfect discrimination.
We assessed the importance of each variable in the
prognostic model by examining the impact that re-
moving the variable from the model had on D and
R2D , both by removing just one of the variables, and
then by sequentially removing the variables from the
model [28].Development of the melanoma severity index (MSI)
While a complete prognostic model containing all sig-
nificant covariates may have its advantages, in particular
being able to explain the greatest amount of variation in
survival, a parsimonious model containing only import-
ant predictors may be preferred for clinical application
[29]. To develop this reduced model, known as the MSI,
we based the variable selection on the BIC statistics and
the reduction in the per cent of explained variation
when the variable was removed from the model [29,30].
For illustration, predicted survival probabilities and
survival curves, along with their 95% confidence inter-
vals were then calculated from the MSI based on specific
combinations of the final set of prognostic variables.
Validation and calibration
Calibration reflects prediction accuracy. A well-calibrated
prognostic model assigns the correct mean survival prob-
ability at all levels of predicted risk. We used an internal-
external cross validation (IECV) method [31] for validating
and assessing the calibration of the MSI.
Briefly, the IECV method involves splitting Queensland
into 9 geographical regions (Figure 1). The MSI is then
fitted using data from eight of these regions. The linear
predictor, Xβ was estimated and applied to both the fit-
ted data (eight regions, “k”) and the excluded data
(remaining 9th region, “(k)”). Values of Royston and
Sauerbrei’s D statistic [28] were calculated from each
result (Dk and D(k) respectively). If the predictive ability
of the model is maintained, both values of D will be
approximately equal. The difference between the two
values (dk) was calculated, with its standard error being
the square root of the sum of the squared standard er-
rors for Dk and D(k). This process was repeated across
the nine geographical regions.
Figure 1 Regions for internal-external validation, Queensland, Australia.
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comparing the predicted mean survival curves in each
geographical region with the observed Kaplan-Meier
survival estimates in that region.
Results
Patient characteristics
Of 35,264 patients diagnosed with invasive melanoma in
Queensland between 1995 and 2008, 34,384 were aged
between 20 to 89 years at diagnosis, and 28,654 had no
other histologically confirmed invasive melanoma diag-
nosed since 1982 (Table 1). The median follow up time,
calculated as the median time to censoring, was 7.2 years.
A total of 5,469 (19%) had died before the 31st December
2010. Almost a third of these deaths (31%) were ascribed
to melanoma.
Multivariable analysis
All variables shown in Table 1 were considered in the
initial prognostic model (see Figure 2). There was some
evidence that sub-site had a time-dependent regression
coefficient, so that the survival differential by subsite
varied on the probit scale by follow up interval. Howeverthe effect was small and of no clinical relevance, and
so was not included in the final model. Therefore,
the selected model had no time-dependent regression
coefficients.
Age at diagnosis was included in the model as a non-
transformed continuous variable. Accurate modeling
of the key predictor, thickness, was critical and was
done in two stages. First, a smooth rank transform
(SRT_thickness) was generated using the acd command
in Stata [27] and further transformed for inclusion in the
model (SRT_thickness2). Lack of fit was still apparent, so
the original continuous thickness term was also included.
The resulting analysis of martingale residuals showed sat-
isfactory fit (results not shown).Concordance and discrimination
The effect of each variable on the discrimination (D)
and explained variation (R2D ) are shown in Table 2.
The final model explained 49% of the variation, with
a D statistic of 1.55. Clearly, the majority of this per-
formance was provided by the transformed thickness
variables, with thickness alone accounting for nearly
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
Male Female
Sex
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
20-39 40-59 60-69
70-79 80-89
Age at diagnosis
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 13 16
Years since diagnosis
SSM NM MM in JN
LMM ALM Other spec
MM NOS
Morphology
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 13 16
Years since diagnosis
No ulceration Known ulceration
Ulceration
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
Into papillary dermis
Into reticular dermis Into subc fat
Clarks Level
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 13 16
Years since diagnosis
<=0.50mm 0.51-1.00mm
1.01-1.50mm 1.51-2.00mm
2.01-4.00mm 4.01mm+
Thickness2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
Scalp Face/Lip/eyelid Ear/neck
chest/Axilla Abdomen/Hip
Subsite (a)
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
Back/buttocks Arm/Hand/fingers Foot/heel/toes
Leg/ankle Shoulder
Subsite (b)
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
None Positive nodes
Positive nodes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
u
rv
iv
a
l 
p
ro
b
a
b
il
it
y
0 1 3 5 7 10 13 16
Years since diagnosis
No mets Distant mets
Distant metastasis
Filling papillary dermis
Figure 2 Kaplan-Meier survival estimates by covariate group (1995–2008, follow up to 2010).
Table 2 Effect of removing and adding variables from the prognostic model (Probit model with 3df) on discrimination (D)
and explained variation (R2D)
Removing variable Adding variable
Variable Singlea Cumulativeb Single variable only Added to thickness
D R2D Order D R
2
D D R
2
D Harrell’s C D
d R2D
d
<full model> 1.526 0.478
Clark’s level 1.521 0.476 1 1.521 0.476 1.108 0.325 0.815 0.006 0.002
Morphology 1.519 0.475 2 1.513 0.473 0.643 0.140 0.699 0.017 0.006
Gender 1.513 0.473 3 1.500 0.469 0.277 0.029 0.569 0.038 0.014
Agec 1.504 0.470 4 1.467 0.458 0.398 0.058 0.646 0.042 0.015
Positive lymph nodes 1.504 0.470 5 1.457 0.451 0.990 0.278 0.541 0.038 0.014
Ulceration 1.503 0.470 6 1.409 0.438 0.998 0.281 0.715 0.044 0.016
metastasis 1.494 0.467 7 1.358 0.420 1.068 0.309 0.530 0.053 0.019
Body site 1.490 0.466 8 1.307 0.401 0.303 0.035 0.600 0.052 0.019
Thicknessc 1.354 0.419 9 - - 1.307 0.401 0.866
aBased on the prognostic regression model after removing only the given variable.
bBased on the prognostic regression model after sequentially removing the variables in the stated order (1 = first, 2 = second, ..).
cTreated as transformed continuous variables (see text for details). The remaining variables are categorical.
dValues represent the difference in fit statistics between the model with thickness only cand the model including thickness cand the shown variable.
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Baade et al. BMC Cancer  (2015) 15:27 Page 7 of 1341% of the variance and a D statistic of 1.32. However,
when the remaining variables were combined, excluding
thickness, they were able to explain similar amounts of
the survival (R2D ¼ 0:44; D ¼ 1:40) as thickness alone.
This result suggests relatively high correlation among the
predictors. As variables entered as single variables in a
model, the most discriminative variables were (in order)
thickness, Clark’s level and metastasis. However, when
removed from the full model (Table 2), Clark’s level
(D: 0.005 and R2D : 0:002), morphology (D: 0.008 and
R2D : 0:003) and gender (D: 0.013 and R
2
D : 0:006) de-
creased the discrimination by small amounts and the
explained variation by less than one percent. The
BIC statistic was minimized by excluding Clark’s level and
Morphology. Finally, Clark’s level, morphology and gender
were removed to form the “parsimonious” model, hereby
referred to as the Melanoma Severity Index (MSI).
The Harrell-C statistic for the full model was 0.89
(95% CI = 0.890, 0.894), and 0.88 (0.877, 0.892) for the
MSI. Generally the Harrell-C statistics for the individ-
ual variables were strongly correlated with the D and
R2D statistics (Table 2), with the exception of metasta-
ses and positive lymph nodes. Both these variables had
low prevalence (Table 1). Additional unpublished sen-
sitivity analyses suggested that the performance of the
Harrell-C statistic in quantifying predictive ability of a
variable depends on the prevalence of the feature in
question.Final parameter estimates
The parameter estimates from the full and the MSI mul-
tivariable probit regression model are shown in Table 3.
The interpretation of the coefficients from this model is
less familiar in a medical context than, for example, the
coefficients from linear or logistic regression.
A one-unit change in a covariate results in a one-beta
change in risk on the probit (inverse normal probability)
scale, where beta is the regression coefficient for the
variable in question. However, in a more general sense, a
positive beta coefficient means that an increase in the
covariate raises the predicted probability of death from
melanoma. Conversely, a negative beta coefficient means
that an increase in the covariate reduces the predicted
probability of death.
The full model shows that the probability of death
from melanoma was higher among males, older patients,
those with thicker melanomas, lesions diagnosed on the
scalp, abdomen/hip and foot, nodular melanomas, those
with known ulceration, those with positive lymph nodes,
evidence of distance metastasis and those with increas-
ing level of invasion (Table 3). Similar direction and
magnitude of effects for the included variables were ob-
served for the MSI model (Table 3).Internal-external validation
The results of our internal-external cross validation
(Figure 3, Table 4) suggests there is limited hetero-
geneity of the discrimination of the MSI model across
the nine geographical regions of Queensland. The only
exception was for Region 3, for which the model based
on the rest of Queensland had higher discrimination
when applied to this region. The mean survival curves
predicted by the model generally agreed well with the ob-
served (Kaplan-Meier) survival curves (Figure 3).
Examples of model predictions for individual patients
Examples of the estimated survival probabilities gener-
ated by the MSI for twelve hypothetical patients present-
ing with specific combinations of clinical characteristics
and demographics are shown in Table 5 (and Figure 4),
with comparison estimates generated by the AJCC Mel-
anoma Patient Outcome Prediction Tool [32]. For ex-
ample, the estimated 10-year survival of a 55 year old
person diagnosed with a 0.45 mm thick melanoma on
the back with no evidence of ulceration, positive lymph
nodes or metastasis (Example 2) was 98.3%. In compari-
son, a the 10 year survival for a 75-year old person diag-
nosed with a 2.45 mm thick melanoma on the back with
evidence of ulceration, but no positive lymph nodes or
metastasis (Example 8) was 61.4%.
When comparing the MSI and the MPOPT (Table 5),
the predicted 10-year survival percentages for MSI were
generally higher than for the MPOPT, with the excep-
tion of the two most advanced cases of melanoma.
Discussion
This prognostic model for people diagnosed with inva-
sive melanoma was developed using a large population-
based dataset containing information about the recognized
prognostic features of melanoma with up to 16 years of
follow-up. The flexible parametric survival model used for
this development has many advantages over the standard
Cox model used by previous studies, and the population-
based registry cohort removed the inherent biases associ-
ated with cohorts based on hospital clinic patients. In
addition, by extracting additional clinical features from
pathology forms, we were able to include clinical factors
such as ulceration, number of positive lymph nodes and
the presence of metastasis that are not typically available in
these population-based data.
There are several benefits of a prognostic model over
and above those provided by standard Kaplan-Meier es-
timates. First, by incorporating demographic and clinical
factors, the MSI output can be specifically targeted to an
individual. Comparable Kaplan-Meier statistics would
need to be generated from stratified subsamples, typic-
ally containing insufficient numbers to generate reliable
estimates. Second, by incorporating the flexible parametric
Table 3 Multivariable parameter estimates from the Full and MSI modelsa
Variable Beta coefficient [95% confidence interval]
Full model MSI model
Gender
Male 0.000a Not included
Female −0.147 [−0.207, −0.086]
Age at diagnosis (transformed) 0.007 [0.005, 0.008] 0.007 [0.005, 0.009]
Thickness (original) 0.044 [0.030, 0.058] 0.038 [0.025, 0.050]
SRT_Thickness (transformed)b 1.593 [1.394, 1.792] 1.830 [1.697, 1.963]
Body site
Scalp 0.376 [0.233, 0.519] 0.348 [0.210, 0.486]
Face/Lip/Eyelid −0.063 [−0.173, 0.046] −0.110 [−0.215, −0.004]
Ear/Neck −0.025 [−0.141, 0.091] −0.041 [−0.156, 0.073]
Chest/Axilla −0.108 [−0.250, 0.033] −0.102 [−0.244, 0.039]
Abdomen + Hip 0.148 [−0.010, 0.307] 0.143 [−0.015, 0.301]
Back/Buttocks 0.000a 0.000a
Upper arm/Forearm/Hand/Finger/sb.handc −0.321 [−0.425, −0.218] −0.361 [−0.463, −0.259]
Foot/sb.foot/heel/toec 0.174 [−0.031, 0.378] 0.089 [−0.089, 0.267]
Thigh/leg/ankle −0.251 [−0.339, −0.163] −0.291 [−0.376, −0.206]
Shoulder −0.079 [−0.187, 0.029] −0.099 [−0.207, 0.009]
Morphology
Not included
SSM 0.000a
Nodular melanoma 0.076 [−0.005, 0.158]
MM in junctional naevus 0.085 [−0.154, 0.325]
Lentigo Maligna melanoma −0.084 [−0.244, 0.077]
Acral lentiginous melanoma −0.081 [−0.402, 0.241]
Other specified melanoma −0.232 [−0.355, −0.109]
Malignant melanoma NOSd 0.014 [−0.057, 0.086]
Ulceration
No ulceration 0.000a 0.000a
Known ulceration 0.357 [0.277, 0.437] 0.378 [0.300, 0.456]
Positive lymph nodes
None 0.000a 0.000a
At least one 0.753 [0.593, 0.912] 0.779 [0.620, 0.938]
Metastasis
No 0.000a 0.000a
Yes 1.062 [0.861, 1.262] 1.062 [0.861, 1.262]
Clarks Level
Into papillary dermis 0.000a
Not included
Filling papillary dermis 0.153 [0.052, 0.253]
Into reticular dermis 0.193 [0.072, 0.314]
Into subcutaneous fat 0.197 [0.024, 0.370]
Note: adenotes the reference category.
bSRT_Thickness is the smooth rank transform of the thickness variable (see Methods for details).
csb = subungal; dNOS = Not otherwise specified.
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Figure 3 Predicted and observed survival curves by region from the internal–external cross-validation approach.
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generate other estimates of survival, including longer-term
survival, conditional survival and the predicted life expect-
ancy following a melanoma diagnosis.
The single most important feature in the prognostic
model was thickness. This has been shown to be an im-
portant predictor in previous models, [11,13,32,33] evenTable 4 Evaluation of heterogeneity of the measure of separa
regions: internal–external cross-validation using the MSI mod
Region (k)1 Nk Melanoma deathsk Other deathsk D(k)Omi
1 1,294 84 150 1.50
2 1,438 80 151 1.50
3 919 54 101 1.49
4 1,574 91 192 1.49
5 1,461 104 204 1.50
6 2,313 138 287 1.49
7 3.495 216 446 1.53
8 10,578 601 1,376 1.52
9 3,982 212 489 1.53
1Cases for which the geographical region was undefined (n = 1,600, 120 melanomawhen restricted to localized [13] or thin [2] melanomas.
The MSI can be used to highlight the importance of de-
tecting melanoma early from a public health perspective
by quantifying the expected reduction in survival as the
thickness at diagnosis increases.
While this prognostic model has not yet been vali-
dated against an external, independent dataset, wetion (Discrimination, D) across geographically defined
el
tting region k DkPredicted in region k dk(= Dk– D(k)) SE (dk)
1.57 0.07 0.14
1.51 0.01 0.14
2.34 0.85 0.24
1.73 0.24 0.14
1.52 0.01 0.13
1.75 0.26 0.12
1.38 −0.15 0.08
1.46 −0.06 0.06
1.40 −0.13 0.09
deaths, 373 other deaths) were retained in the validation process.
Table 5 Predicted 10-year survival percentages for twelve hypothetical melanoma patients using the MSI, including
comparisons with the AJCC Melanoma Patient Outcome Prediction Tool (MPOPT)a
Characteristic Estimated survival (%) after ten years
Age Thick (mm) Site Ulceration Positive lymph nodes Mets MSI MPOPTa
1. 35 0.45 Back No No No 98.8 [99–99] 97.5 [97–99]
2. 55 0.45 Back No No No 98.3 [98–99] 97.5 [97–99]
3. 55 1.00 Back No No No 91.7 [91–93] 90.0 [88–92]
4. 75 1.00 Back No No No 89.4 [88–91] 82.8 [78–88]
5. 55 1.45 Back No No No 86.2 [85–88] 83.7 [82–86]
6. 75 1.45 Back No No No 83.0 [81–85] 69.6 [63–77]
7. 75 2.45 Back No No No 74.8 [72–77] 59.6 [51–69]
8. 75 2.45 Back Yes No No 61.4 [58–64] 42.0 [33–54]
9. 75 4.45 Scalp Yes No No 38.9 [34–44] 35.2 [27–47]
10. 85 4.45 Scalp Yes No No 36.3 [31-42] 35.2 [27–47]
11. 75 4.45 Scalp Yes Yes No 14.5 [10–20] 29.1 [22–39]
12. 75 4.45 Scalp Yes Yes Yes 1.7 [1–3] 15.9 [6–44]
Notes: aFor comparison with the MPOPT (www.melanomaprognosis.org), Scalp and Back were categories as “Axial”, and positive lymph nodes or metastasis were
both considered indicative of “Regional metastasis).
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Figure 4 Predicted 10-year mean survival curves, for twelve hypothetical melanoma patients.
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Baade et al. BMC Cancer  (2015) 15:27 Page 11 of 13have examined the internal reliability by assessing its
consistency across a variety of different geographical
areas within the state, areas that are characterized by
differing health patterns and life expectancy. These
unmeasured factors are not considered by the prog-
nostic model, so the consistency of the model’s discrimin-
atory performance across these regions is encouraging.
Validation using an external dataset would entail calculat-
ing the prognostic index using the parameter estimates
from this study cohort applied to the covariate values of
the secondary dataset. Similarly, the baseline survival func-
tion is calculated in the external dataset using both the
parameter vector from this study cohort, together with the
(log) time values in the external dataset and the set of
spline knots used in the current cohort [34].
We did not have information on mitotic rate, and thus
have not been able to examine the effect this had on
melanoma survival. Mitotic rate is recognized as an im-
portant prognostic factor in the final version of the 2009
AJCC Melanoma Staging and Classification [11]. That
this variable was omitted here is a limitation. In addition
there are other factors that have been shown to influ-
ence melanoma survival that have not been included in
this model [33], such as HIV infection, race and socio-
economic status. We also did not have information
about concomitant diseases that may have independently
lowered predicted survival. Importantly, we did include
variables that were demonstrated by others to be signifi-
cant predictors of melanoma survival by other studies,
notably thickness, age, body site and ulceration [13,32].
The use of multiple imputation for missing data as-
sumed that the data are missing at random (MAR). We
were not able to rule out that the data are missing not at
random (MNAR), and it remains possible that there is
some unmeasured characteristic of the treating clinician
or pathology laboratory that impacted on the complete-
ness of the registry data. Finally, since we included only
patients with one diagnosed melanoma to ensure a
greater link between the melanoma characteristics and
survival outcome, the predicted survival outcomes would
no longer be relevant if a subsequent melanoma was
diagnosed.
Given the variation in cohort selection, clinical charac-
teristics and statistical methods, direct comparisons with
the results of our study to those published recently
[2,13,32] for melanoma are difficult. In particular, the
comparisons with the AJCC Melanoma Patient Outcome
Prediction Tool (United States) [13,32] demonstrate
there are important differences between the two coun-
tries. It is unknown whether this is due to the statistical
method or to cohort selection, since the MPOPT is
based on patients selected from major cancer centres
and clinical trial cooperative groups. Alternatively, differ-
ences in diagnostic or management practices may have ledto important differences in the survival outcomes expected
by people diagnosed with melanoma in the two countries.
From a clinical perspective, this MSI could be readily
applied to individual melanoma patients. We plan to
incorporate a MSI online dissemination tool into a
broader package for primary care physicians to assist in
discussions about prognosis in the clinical setting.
One of the many advantages of using the flexible para-
metric modeling approach is that these models can be
readily extended to consider estimates of conditional
survival [20] and loss of life expectancy [35] due to their
diagnosis in comparison to the general population. We
have previously shown that people diagnosed with local-
ized or regional melanoma have negligible excess mor-
tality compared to the general population once they
have survived ten years post-diagnosis [36,37]. Such
models enable more precise estimates of conditional sur-
vival by incorporating clinically relevant factors in the
estimation. Further work is also planned on the impact
of competing risks within the flexible parametric frame-
work [20,38].
We did not find any time-dependent regression coeffi-
cients of sufficient impact to include them in the final
model. Proponents of other prognostic models using
large epidemiological cancer datasets have observed
time-varying coefficients [38-40] on a hazard scale.
However, in our probit model, hazard ratios comparing
any two values of a covariate can be shown to tend to-
ward 1 as follow-up time increases. Thus, all hazard
ratios are time-dependent. When there are multiple time-
dependent coefficients, interpreting the time dependent
hazard ratios can be difficult in the log cumulative hazard
framework of the Royston-Parmar models [20]. The rea-
son is that hazard ratios depend on the values of more
than just one covariate. Alternatives, including modelling
on the log excess hazard scale, may offer more inter-
pretable options when time dependent coefficients are
present [41].
Conclusions
The MSI serves to identify and weight key parameters of
prognostic importance in melanoma, and therefore allow
a finer gradation of the prognostic value of interventions
than the simple dichotomous variable of death due to
melanoma, with greater statistical power for compari-
sons. It also enables predictions of survival outcomes
soon after the intervention, rather having a 5 or ten year
delay for follow-up. Thus, beyond the immediate clinical
use, the MSI may have important public health and re-
search applications for evaluations of public health inter-
ventions aimed at reducing deaths from melanoma.
Abbreviation
MSI: Melanoma severity index.
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